Skip to main content
Clinical Trials/NCT05366413
NCT05366413
Completed
N/A

Pilot Study of Early Referral to Interventional Pain Management for Patients With Advanced Malignancies

Dana-Farber Cancer Institute2 sites in 1 country30 target enrollmentJune 2, 2022
ConditionsCancer Pain

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cancer Pain
Sponsor
Dana-Farber Cancer Institute
Enrollment
30
Locations
2
Primary Endpoint
Feasibility - Pain Consultation
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of the study is to evaluate how feasible and beneficial it is to refer patients with cancer pain to a doctor who specializes in pain management, including procedures to relieve pain, and whether this is helpful to patients with pain related to their cancer.

Detailed Description

This is a single arm pilot study evaluating a new system of referral and pain evaluation for patients with advanced solid tumors and moderate-to-severe pain who are not already on high-dose opioids to an anesthesia-trained interventional pain management specialist . A variety of interventional treatments for pain have been proven effective for cancer patients. Often without early referral patients do not get evaluated for interventional procedures for their pain unless the pain is very severe, or they are admitted to the hospital. It is expect this intervention will work by providing effective pain treatments to patients sooner than they might normally be referred and will be evaluated by how many patients are candidates for interventional treatments for their pain, whether patients choose to receive these treatments, and whether patients find the pain specialist referral acceptable and helpful The research study procedures include screening for eligibility, study interventions including evaluations and follow up visits, as well as surveys at the beginning, middle, and end of the study. Participants will be followed on the study for 4 months. It is expected that about 30 people will take part in this research study. Medtronic and is providing funding for this research study

Registry
clinicaltrials.gov
Start Date
June 2, 2022
End Date
October 26, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Andrea Enzinger, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of a metastatic, or locally advanced unresectable malignancy
  • Anticipated prognosis of more than 6 months according to the primary oncologist
  • Age greater than 21 years
  • Persistent pain with an average pain rating of 4 or greater on an 11-point numeric rating scale (NRS) from 0-10 where 10 is considered the most severe.
  • Pain has persisted for at least 2 weeks
  • Pain is due to cancer or sequelae of cancer treatment

Exclusion Criteria

  • Primary pain syndrome is sensory peripheral neuropathy
  • Patient is taking more than 200 morphine milligram equivalents (MMEs) per day on average, at the time of recruitment.
  • Currently cared for by interventional pain management specialist
  • Receipt of prior pain intervention (e.g. celiac neurolysis)
  • Bleeding diathesis, uncontrollable infection, or other contra-indications to pain interventions
  • History of opioid misuse disorder
  • Inability to speak English
  • Cognitive impairment or any other disorder that would impede study participation and survey completion
  • If patients are unable to complete the baseline survey, they will no longer be considered eligible for the study; this will serve as an indication of barriers to participation that would make them unable to comply with study procedures.

Outcomes

Primary Outcomes

Feasibility - Pain Consultation

Time Frame: 4 Weeks

Feasibility will be measured by the percentage of patients that have an interventional pain consultation within 4 weeks, with a threshold for determining feasibility of at least 80% of participants.

Feasibility - Interventional Pain Procedure Rate

Time Frame: 4 Months

Feasibility will be measured by the percentage of patients who ultimately receive at least one interventional pain procedure, with a threshold for determining feasibility of at least 50% of participants.

Acceptability - Satisfaction Ratings

Time Frame: 4 Months

Acceptability will be measured by the percentage of patients satisfied with their interventional pain management care, with a threshold of at least 80% of patients rating the quality of care received at the interventional pain management clinic at a 7 or above on a 0-10 scale (adapted from HCAHPS; 0 being the worst clinic possible, 10 being the best clinic possible). For participants with missing data at 4-months, we imputed their responses at 2-months.

Study Sites (2)

Loading locations...

Similar Trials